EGFR and triple-negative breast carcinoma: Moreover, NONO contributes to oncogenesis, chemotherapy resistance, and poor prognosis in triple-negative breast cancer (TNBC) by modulating Epidermal Growth Factor Receptor (EGFR) and Signal Transducer And Activator Of Transcription 3 (STAT3) stability [10,11].